Assessing Quality of Life in Long-Term Survivors after 125I Brachytherapy for Low-Grade Glioma in Childhood

R. Korinthenberg; D. Neuburger; G. Nikkhah; C. Teske; K. Schnabel; G. Calaminus

doi:10.1055/s-0031-1283111

Neuropediatrics, Inhaltsverzeichnis

Neuropediatrics 2011; 42(03): 110-115
DOI: 10.1055/s-0031-1283111

Original Article

Georg Thieme Verlag KG Stuttgart · New York

Assessing Quality of Life in Long-Term Survivors after ¹²⁵I Brachytherapy for Low-Grade Glioma in Childhood

Autoren

R. Korinthenberg

¹Division of Neuropediatrics and Muscular Disorders, Department of Pediatrics and Adolescent Medicine, University Hospital, Albert-Ludwigs University, Freiburg im Breisgau, Germany
D. Neuburger

¹Division of Neuropediatrics and Muscular Disorders, Department of Pediatrics and Adolescent Medicine, University Hospital, Albert-Ludwigs University, Freiburg im Breisgau, Germany
G. Nikkhah

²Department of Stereotactic Neurosurgery, Neurocenter, University Hospital, Albert-Ludwigs University, Freiburg im Breisgau, Germany
C. Teske

³Department of Pediatric Hematology and Oncology, University Hospital, Westfälische Wilhelms University, Münster, Germany
K. Schnabel

³Department of Pediatric Hematology and Oncology, University Hospital, Westfälische Wilhelms University, Münster, Germany
G. Calaminus

³Department of Pediatric Hematology and Oncology, University Hospital, Westfälische Wilhelms University, Münster, Germany

Abstract

Quality of life (QOL) is important for the survivors of malignancies. We investigated health-related QOL in 51 patients treated with iodine-125 (¹²⁵I) brachytherapy for childhood low-grade gliomas. Instruments included a questionnaire on life situation, German versions of PEDQOL (8−18 years), EORTC QLQ-30 and head and neck module H&N-35 (>18 years), strength and difficulties questionnaire, “Fertigkeitsskala Münster Heidelberg”, and an adapted Rankin score. The time lapsed since ¹²⁵I-brachytherapy was 134 months (median, range: 29−293 months). 57% of the patients were over 18 years of age, 34% were 11−17 years old and 8% were younger. 14 had undergone other treatments after ¹²⁵I brachytherapy. Over half of the >18 year olds reported residual problems; 68% were disabled, 38% to a severe degree. Many of the young adults still lived with their parents and 17% were jobless. 43% of the children/adolescents needed rehabilitative treatment, 20% visited special schools and 71% were disabled, 33% severely. The patients and their caregivers rated their QOL as not different from that of the normal population. However, many QOL dimensions correlated to the severity of disability. Comparison of QOL outcomes between different treatment measures would require a prospective study controlling for the most important factors of influence.

Key words

children - glioma - iodine-125 brachytherapy - quality of life - long-term follow-up

Volltext

Referenzen

References
1 Aaronson NK, Ahmedzai S, Bergman B et al. QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376
2 Aarsen FK, Paquier PF, Reddingius RE et al. Functional outcome after low-grade astrocytoma treatment in childhood. Cancer 2006; 106: 396-402
3 Benesch M, Lackner H, Sovinz P et al. Late sequela after treatment of childhood low-grade gliomas: a retrospective analysis of 69 long-term survivors treated between 1983 and 2003. J Neurooncol 2006; 78: 199-205
4 Bjordal K, Kaasa S. Psychometric validation of the EORTC core quality of life questionnaire, 30 item version and a diagnosis specific module for head and neck cancer patients. Acta Oncol 1992; 31: 311-321
5 Calaminus G, Weinspach S, Teske C et al. Quality of life in children and adolescents with cancer. First evaluation of 49 patients with the PEDQOL questionnaire. Klin Pädiatr 2000; 212: 211-215
6 Calaminus G, Weinspach S, Teske C et al. Quality of survival in children and adolescents after treatment for childhood cancer: the influence of reported late effects on health related quality of life. Klin Padiatr 2007; 219: 152-157
7 Dickinson HO, Parkinson KN, Ravens-Sieberer U et al. Self-reported quality of life of 8- − 12-year-old children with cerebral palsy: a cross-sectional European study. Lancet 2007; 369: 2171-2178
8 Fisher PG, Tihan T, Goldthwaite PT et al. Outcome analysis of childhood low-grade astrocytomas. Pediatr Blood Cancer 2008; 51: 245-250
9 Fouladi M, Wallace D, Langston JW et al. Survival and functional outcome of children with hypothalamic/chiasmatic tumors. Cancer 2003; 97: 1084-1092
10 Goodman R. Psychometric properties of the strengths and difficulties questionnaire (SDQ). J Am Acad Child Adolesc Psychiatry 2001; 40: 1337-1345
11 Klasen H, Woerner W, Wolke D et al. Comparing the German versions of the strengths and difficulties questionnaire (SDQ-Deu) and the child behavior checklist. Eur Child Adolesc Psychiatry 2000; 9: 271-276
12 Korinthenberg R, Neuburger D, Trippel M et al. Long-term results of brachytherapy with temporary iodine-125 seeds in children with low-grade gliomas. Int J Radiation Oncology Biol Phys 2010;
13 Lannering B, Marky I, Lundberg A et al. Long-term sequelae after pediatric brain tumors: their effect on disability and quality of life. Med Pediatr Oncol 1990; 18: 304-310
14 Lulé D, Zickler C, Häcker S et al. Life can be worth living in locked-in syndrome. Prog Brain Res 2009; 177: 339-351
15 Mostow EN, Byrne J, Connelly RR et al. Quality of life in long-term survivors of CNS tumors of childhood and adolescence. J Clin Oncol 1991; 9: 529-592
16 Mulhern RK, Hancock J, Fairclough D et al. Neuropsychological status of children treated for brain tumors: a critical review and integrative analysis. Med Pediatr Oncol 1992; 20: 181-191
17 Osoba D, Aaronson NK, Muller M et al. The development and psychometric validation of a brain cancer quality of life questionnaire for use in combination with general cancer specific questionnaires. Quality of Life Res 1996; 5: 139-150
18 Packer RJ, Gurney JG, Punyko JA et al. Long-term neurologic and neurosensory sequelae in adult survivors of a childhood brain tumor: childhood cancer survivor study. J Clin Oncol 2003; 21: 3255-3261
19 Pompili A, Caperle M, Pace A et al. Quality-of-life assessment in patients who had been surgically treated for cerebellar pilocytic astrocytoma in childhood. J Neurosurg 2002; 96: 229-234
20 Ribi K, Relly C, Landolt MA et al. Outcome of medulloblastoma in children: long-term complications and quality of life. Neuropediatrics 2005; 36: 357-365
21 Ringdal GI, Ringdal K. Testing the EORTC Quality of life questionnaire on cancer patients with heterogeneous diagnoses. Quality of Life Res 1993; 2: 129-140
22 Ris MD, Beebe DW. Neurodevelopmental outcomes of children with low-grade gliomas. Dev Disabil Res Rev 2008; 14: 196-202
23 White-Koning M, Arnaud C, Dickinson HO et al. Determinants of child-parent agreement in quality-of-life reports: a European study of children with cerebral palsy. Pediatrics 2007; 120: e804-e814
24 Woerner W, Becker A, Friedrich C et al. Normierung und Evaluation der deutschen Elternversion des Strengths and Difficulties Questionnaire (SDQ): Ergebnisse einer repräsentativen Felderhebung. Z Kinder- Jugendpsychiatrie Psychotherapie 2002; 30: 105-112
25 Wolff JE, Däumling E, Dirksen A et al. Munster Heidelberg abilities Scale – a measuring instrument for global comparison of illness sequelae [Article in German] Klin Padiatr 1996; 208: 294-298
26 Wolff JE, Hüttermann U, Askins MA. Quantifying health status outcomes in pediatric medulloblastoma patients. Anticancer Res 2007; 27: 523-529